# Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

> **NCT00005874** · PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.**

## Conditions studied

- Gastrointestinal Stromal Tumor
- Sarcoma
- Small Intestine Cancer

## Interventions

- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00005874
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005874, "Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*